Innate Pharma (IPHA) Other Non-Current Liabilities (2017 - 2025)

Innate Pharma (IPHA) has reported Other Non-Current Liabilities for 9 consecutive years, with $377800.8 the latest figure, recorded in Q4 2025.

• Quarterly Other Non-Current Liabilities rose 21.17% year-over-year to $377800.8 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $377800.8 (up 21.17% YoY) and the FY2025 annual result came in at $377800.8, up 21.17% from the prior year.
• Other Non-Current Liabilities slipped to $377800.8 in Q4 2025 per IPHA's latest filing, from $1.3 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for IPHA reached as high as $6.4 million in Q2 2021 and fell as low as $225314.9 in Q4 2022.
• A 5-year average of $1.3 million and a median of $556459.6 in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Other Non-Current Liabilities sank 97.56% — and 2023, when it jumped 204.55%.
• Year by year, Other Non-Current Liabilities stood at $287902.4 in 2021, then declined by 21.74% to $225314.9 in 2022, then soared by 204.55% to $686186.4 in 2023, then sank by 54.56% to $311799.5 in 2024, then rose by 21.17% to $377800.8 in 2025.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $377800.8, $1.3 million, and $311799.5 for Q4 2025, Q2 2025, and Q4 2024 respectively.